| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cosmos Health Inc.$0.21
-0.03 (-11.92%)
Market Cap
13.74 M
EPS
-0.65
P/E Ratio
-
Value Trade
399.70 K
SEC Financials
Q1 2026Dilution Risk
Revenue
17.93 M
R&D Expenses
-
Operating CF
-1.07 M
Total Assets
62.37 M
Total Liabilities
42.54 M
Equity
19.83 M
D/E Ratio
12,345
-17.59 %
Week
-26 %
1 Month
-34.47 %
3 Month
-60.17 %
6 Month
-99.81 %
5 Year
-99.92 %
All Time
Cash Data
Cash Position
2.16 M
Monthly Burn
356.00 K
Runway
5.1 mo
Burn Trend
SEC Filing
May 20, 2026
Overview
Volume
16.62 M
52 Week Range
0.25 - 1.32
% held by Insiders
66.93 %
% held by Institutions
2.37 %
Enterprise Value
30.03 M
Total Shares
59.97 M
Short %
2.01 %
Float Shares
44.38 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COSM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Cosmos Health Inc. (COSM) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
COSM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COSM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COSM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COSM Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
COSM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COSMCosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity
Cosmos Health Inc. reported a record revenue of over $15 million for Q2 2026, indicating a strong annualized run-rate of over $60 million. The company's subsidiary, CosmoFarm, expanded its distribution network by adding more than 80 pharmacies. To support this growth, Cosmos Health is investing in AI automation and expanding its facility capacity.
Read more →COSMCosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States
Cosmos Health Inc. has entered the global skincare market with a new collagen-based skincare line, which has already begun sales in the U.S. The company aims to diversify its portfolio and capitalize on the high-growth skincare segment, projected to reach $203 billion by 2033. CEO Greg Siok highlighted the strategic importance of this move for the company's growth.
Read more →COSMCosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products
Cosmos Health Inc. has announced a five-year contract manufacturing agreement with Pharmex S.A. to produce three dermatological products, totaling approximately 2.86 million units. This partnership aims to enhance Cosmos Health's manufacturing capabilities and strengthen its role in contract manufacturing. The agreement reflects the trust in Cana Laboratories' production capabilities and is expected to generate stable, recurring revenue.
Read more →COSMCosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
Cosmos Health Inc. has launched its 18 Series nutraceutical products in the U.S., projecting over $22.7 million in annual revenue and around $17 million in gross profit. The company reports strong early demand and aims to expand its product portfolio to 18 items. CEO Greg Siokas emphasizes the focus on profitability and future growth.
Read more →COSMCosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines
Cosmos Health Inc. announced that its subsidiary, Cana Laboratories, has secured new contract manufacturing orders totaling 253,657 units for various pharmaceutical products. The orders highlight the growing demand for Cana's manufacturing capabilities and the company's commitment to building a diversified business. CEO Greg Siokas noted the importance of these partnerships for long-term shareholder value.
Read more →COSMCosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit
Cosmos Health reported annualized sales exceeding $1.5 million for its antiseptic brands, C-Scrub and C-Sept, in the UK and Greece. The company plans to expand into the EU, targeting $7.4 million in revenue and $5.3 million in gross profit over the next three years. With gross margins above 70%, these products are becoming key components of Cosmos Health's portfolio.
Read more →COSMCosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
Cosmos Health has signed a letter of intent to acquire Doc Pharma S.A., a GMP-certified pharmaceutical manufacturer. The acquisition aims to enhance Cosmos Health's asset base, profitability, and production capacity. With a state-of-the-art facility and a diverse product portfolio, the deal is expected to support margin expansion and cash flow. The transaction will undergo independent review and is subject to shareholder approval.
Read more →COSMCosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance
Cosmos Health Inc. has received a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share, now due by December 7, 2026. The company is compliant with other listing requirements and aims to enhance shareholder value without resorting to a reverse stock split unless absolutely necessary. CEO Greg Siokas emphasized the company's commitment to executing its business strategy to regain compliance.
Read more →COSMCosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway
Cosmos Health Inc. reported record revenue of $65.3 million for FY2025 and a strong start to Q1 2026. The company is actively expanding into the U.S. market and targeting over $200 million in revenue by 2029. CEO Greg Siokas addressed shareholders, emphasizing the company's commitment to growth and innovation while acknowledging recent share price declines.
Read more →COSMCosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
Cosmos Health Inc. has announced a three-year contract manufacturing agreement with Verisfield S.A. for the production of 3.9 million units of VASCLOR GEST progesterone pessaries. This partnership aims to enhance women's health and reproductive medicine. The agreement is expected to broaden Cana Laboratories' customer base and contribute to the growth of its contract manufacturing segment.
Read more →COSMCosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN
Cosmos Health Inc. has inaugurated a new capsule production line through its subsidiary, Cana Laboratories. This facility will manufacture 385,000 units of the antidepressant CERTORUN over a five-year contract with Provident Pharmaceuticals. The production will enhance the company's revenue and strengthen its manufacturing capabilities. CEO Greg Siokas emphasized the importance of this agreement for long-term growth.
Read more →COSMCosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline
Cosmos Health Inc. has reported a positive balance sheet update, highlighting a decrease in total liabilities and an increase in stockholders' equity. The company is in discussions with the European Investment Bank for financing of up to €25 million and has eliminated a significant portion of its warrant overhang without dilution. Despite these advancements, the company noted a recent decline in its share price without a clear business reason.
Read more →COSMCosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
Cosmos Health Inc. reported significant growth in its pharmaceutical distribution subsidiary, Cosmofarm, with a 20% increase in active customers and improved unit economics. The company is expanding its delivery routes and investing in automation to enhance service quality and capacity. Management anticipates continued growth in 2026, supported by a $1 million investment in robotic infrastructure.
Read more →COSMCosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research
Cosmos Health Inc. announced that Zacks Small-Cap Research has initiated coverage with a valuation of $4.50 per share. The report highlights the company's diversified revenue base, vertical integration, and strong revenue growth outlook, projecting revenues to reach $98.6 million in 2026. Additionally, Cosmos Health's expansion into the U.S. market and advancements in its R&D pipeline were emphasized as key growth drivers.
Read more →COSMCosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units
Cosmos Health Inc. has announced a manufacturing agreement with Libytec Pharmaceutical S.A. for the production of PathMuscle, a muscle relaxant and analgesic combination. The agreement includes a commitment to produce over 1.2 million units over five years, enhancing Cosmos Health's manufacturing capacity and market presence in Greece. CEO Greg Siokas emphasized the strategic importance of this collaboration for the company's growth.
Read more →Competitive Position
How COSM ranks across every disease it competes inCompetitive Position is a premium feature
See how COSM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial